Compare PROV & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROV | FATE |
|---|---|---|
| Founded | 1956 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.4M | 125.6M |
| IPO Year | 2009 | 2013 |
| Metric | PROV | FATE |
|---|---|---|
| Price | $18.15 | $1.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $18.50 | $5.74 |
| AVG Volume (30 Days) | 12.4K | ★ 1.6M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | 10.75 | ★ 29.88 |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $3.36 | N/A |
| Revenue Next Year | $0.24 | N/A |
| P/E Ratio | $17.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.95 | $0.95 |
| 52 Week High | $18.99 | $3.23 |
| Indicator | PROV | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 25.20 |
| Support Level | $18.05 | $1.59 |
| Resistance Level | $18.91 | $2.60 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 3.90 | 1.29 |
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.